Schindler Christoph, Bramlage Peter, Kirch Wilhelm, Ferrario Carlos M
Institute of Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany.
Vasc Health Risk Manag. 2007;3(1):125-37.
The renin-angiotensin-system (RAS) is a cascade of enzymatic reactions resulting ultimately in the formation of angiotensin II. Recent research has expanded the knowledge about the RAS by adding new components to the pathways: angiotensin-(1-5) [Ang-1-5], angiotensin-(1-7) [Ang-(1-7)], angiotensin-(1-9) [Ang-(1-9)], an ACE homologous enzyme, ACE2, and the G-protein-coupled receptor mas as a molecular receptor for Ang-(1-7). Although previous studies provided some conflicting evidence about the relevance of Ang-(1-7) in the regulation of vascular and renal function, data now demonstrate that Ang-(1-7) contributes to the cardiovascular effects of ACE-inhibitors (ACE-1) and AT1-receptor-blockers (ARBs) both in experimental conditions and in humans. This review summarizes and critically discusses the currently available experimental and clinical study evidence for the role of Ang-(1-7) as a vasodilator and anti-trophic peptide in cardiovascular drug therapy. In addition, the potential therapeutic impact of currently available RAS blocking agents (ACE-1 and ARBs) and new agents still under development (renin-inhibitors) on the RAS-effector peptides is highlighted.
肾素-血管紧张素系统（RAS）是一系列酶促反应，最终导致血管紧张素II的形成。最近的研究通过在该途径中添加新成分，扩展了对RAS的认识：血管紧张素-（1-5）[Ang-1-5]、血管紧张素-（1-7）[Ang-（1-7）]、血管紧张素-（1-9）[Ang-（1-9）]、一种ACE同源酶ACE2以及作为Ang-（1-7）分子受体的G蛋白偶联受体mas。尽管先前的研究提供了一些关于Ang-（1-7）在血管和肾功能调节中相关性的相互矛盾的证据，但现在的数据表明，在实验条件和人体中，Ang-（1-7）都有助于血管紧张素转换酶抑制剂（ACE-1）和血管紧张素II 1型受体阻滞剂（ARB）的心血管效应。本综述总结并批判性地讨论了目前关于Ang-（1-7）作为血管舒张剂和抗增殖肽在心血管药物治疗中作用的实验和临床研究证据。此外，还强调了目前可用的RAS阻断剂（ACE-1和ARB）以及仍在开发中的新药（肾素抑制剂）对RAS效应肽的潜在治疗影响。
